Navigation Links
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
Date:1/9/2008

MONTVALE, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, has initiated a challenge of the patents listed by Sanofi-Aventis U.S. LLC in connection with its Eloxatin(R) (Oxaliplatin Aqueous Solution), 5mg/mL Injectable.

Barr filed an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Eloxatin product with the U.S. Food & Drug Administration (FDA), and following FDA notification of the application's acceptance for filing, the Company notified the New Drug Application (NDA) and patent owner.

On January 4, 2008, Sanofi-Aventis U.S. LLC, Sanofi-Aventis and Debiopharm S.A. filed suit in the U.S. District Court of New Jersey to prevent the Company from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Eloxatin (Oxaliplatin Aqueous Solution), 5mg/mL Injectable, used in combination with infusional 5-FU/LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor, and is indicated for the treatment of advanced carcinoma of the colon or rectum. The product had sales of approximately $1.1 billion in the U.S., based on IMS sales data for the 12-months ended October 2007.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its pr
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barr Confirms Patent Challenge of Focalin(R) XR
2. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
3. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
4. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
8. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
11. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... NASA astronaut Scott Kelly , who is ... a year living and working on the International Space Station, ... 7 a.m. EDT Monday, March 9. Kelly will ... the final weeks of his training. The interviews will be ... highlighting his mission training and previous spaceflights. To ...
(Date:3/3/2015)... TORONTO , March 3, 2015 /CNW/- SQI Diagnostics ... and commercializes proprietary technologies and products for advanced ... Ryer CPA, CA, CFE  to its Management team. ... the Company in its transition from a development ... financing initiatives to advance the Company,s capital market ...
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... , March 3, 2015  Rosa & Co. ... drug-disease modeling and simulation research, today announced it has ... American Society for Clinical Pharmacology and Therapeutics meeting in ... 2015.   Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... will present a poster describing a quantitative systems pharmacology ...
Breaking Biology Technology:NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... ONTY ) (TSX: ONY) announced today that it ... common stock and warrants to purchase 2,909,244 shares of its ... May 26, 2009. Oncothyreon sold the shares and warrants for ... a warrant to purchase 0.75 shares of common stock). The ...
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: ... of Research and Development, will be presenting pre-clinical data from ... the American Society of Gene Therapy, which is being held ... from Wednesday, May 27th through to Saturday, May 30th, 2009. ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... for human disease, announced today that the company will be ... programs: LX1031 , an oral drug ... (IBS), and LX1032 , an ...
Cached Biology Technology:Oncothyreon announces closing of $11.1 million registered direct financing 2Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy 3Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week 2Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week 3
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting its ... and has launched a new marketing campaign to solidify ... (CLO).  The new campaign focuses on First ... and shipments. The first headline in the ... Marken,s priorities with its client,s priorities. Marken recognizes the ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... Conservation Biology Institute have discovered why older females are ... to introduce vital new genes into the pool. SCBI ... uteri of 34 cheetahs at eight institutions, and determined ... than 8 years appear normal, the animals, uterine tracks ...
... PhD, professor of obstetrics and gynecology and microbiology ... co-leading a new study funded by a five-year ... Allergy and Infectious Diseases (NIAID). Anderson will investigate ... transiently in tobacco plants (called "plantibodies") to prevent ...
... provides a comprehensive and in-depth documentation of how Native ... varied ecosystems of North America during the past 10,000 ... and questions that have shaped debates regarding the nature ... local environments throughout the Holocene. The volume features ...
Cached Biology News:New discovery positions Smithsonian to bolster genetic diversity among cheetahs 2BUSM professor awarded $13.3 million to study potential treatments to prevent STDs 2
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Biology Products: